BR112022023199A2 - Certas composições químicas e métodos de uso das mesmas - Google Patents

Certas composições químicas e métodos de uso das mesmas

Info

Publication number
BR112022023199A2
BR112022023199A2 BR112022023199A BR112022023199A BR112022023199A2 BR 112022023199 A2 BR112022023199 A2 BR 112022023199A2 BR 112022023199 A BR112022023199 A BR 112022023199A BR 112022023199 A BR112022023199 A BR 112022023199A BR 112022023199 A2 BR112022023199 A2 BR 112022023199A2
Authority
BR
Brazil
Prior art keywords
methods
chemical compositions
certain chemical
disorder
disease
Prior art date
Application number
BR112022023199A
Other languages
English (en)
Inventor
W Konradi Andrei
Huang Chun-Hao
Lee Ko-Chuan
Original Assignee
Algen Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algen Biotechnologies Inc filed Critical Algen Biotechnologies Inc
Publication of BR112022023199A2 publication Critical patent/BR112022023199A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

CERTAS COMPOSIÇÕES QUÍMICAS E MÉTODOS DE USO DAS MESMAS. A presente divulgação fornece inibidores de CDK9. Também são fornecidos métodos de tratamento de uma doença ou distúrbio compreendendo a administração a um sujeito com necessidade de tratamento de um dos inibidores de CDK9 divulgados neste documento. Em algumas modalidades, a doença ou distúrbio a ser tratado é câncer. Em algumas modalidades, a doença ou distúrbio é câncer de fígado.
BR112022023199A 2020-05-15 2021-05-14 Certas composições químicas e métodos de uso das mesmas BR112022023199A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025474P 2020-05-15 2020-05-15
PCT/US2021/032495 WO2021231892A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022023199A2 true BR112022023199A2 (pt) 2023-04-04

Family

ID=76270111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023199A BR112022023199A2 (pt) 2020-05-15 2021-05-14 Certas composições químicas e métodos de uso das mesmas

Country Status (11)

Country Link
US (2) US11591322B2 (pt)
EP (1) EP4149941A1 (pt)
JP (1) JP2023526332A (pt)
KR (1) KR20230051127A (pt)
CN (1) CN116261561A (pt)
AU (1) AU2021273072A1 (pt)
BR (1) BR112022023199A2 (pt)
CA (1) CA3178813A1 (pt)
IL (1) IL298219A (pt)
MX (1) MX2022014356A (pt)
WO (1) WO2021231892A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086417A1 (en) * 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
ATE392210T1 (de) 1999-10-07 2008-05-15 Aguilar Cordova Carlos Estuard Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
AU2004247013B2 (en) 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101065A2 (en) * 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
EP2668162A1 (en) 2011-01-28 2013-12-04 Novartis AG Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
AU2016209321B2 (en) 2015-01-20 2019-05-09 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
JP6919977B2 (ja) 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法

Also Published As

Publication number Publication date
EP4149941A1 (en) 2023-03-22
AU2021273072A1 (en) 2022-12-15
MX2022014356A (es) 2023-03-09
KR20230051127A (ko) 2023-04-17
CA3178813A1 (en) 2021-11-18
WO2021231892A1 (en) 2021-11-18
CN116261561A (zh) 2023-06-13
US11591322B2 (en) 2023-02-28
US20230295135A1 (en) 2023-09-21
JP2023526332A (ja) 2023-06-21
US20220289725A1 (en) 2022-09-15
IL298219A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA202190630A1 (ru) Способы комбинированной терапии
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA202092154A1 (ru) Комбинированная терапия
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
EA201391286A1 (ru) Лечение солидных опухолей
BR112018074619A2 (pt) uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer
BRPI0517976A (pt) métodos de tratamento
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
BR112021019466A2 (pt) Biomarcadores de câncer para benefícios clínicos duráveis
MX2022016355A (es) Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
BR112022023199A2 (pt) Certas composições químicas e métodos de uso das mesmas
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.
EA201270298A1 (ru) Способ лечения злокачественной опухоли